Veracyte insider reports tax-withheld RSU shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
VERACYTE, INC. Chief Scientific & Medical Officer Phillip G. Febbo reported a routine share disposition tied to equity compensation. On June 2, 2026, 3,730 shares of common stock were withheld at $47.80 per share to cover tax withholding obligations from vesting restricted stock units, and the company notes this does not represent a market sale. Following this tax withholding event, Febbo directly holds 149,797 shares of common stock.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 3,730 | $47.80 | $178K |
Footnotes (1)
- F1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.
Key Figures
Key Terms
restricted stock units financial
tax withholding obligations financial
Common Stock financial
tax-withholding disposition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Veracyte (VCYT) report for Phillip G. Febbo?
Was the Veracyte (VCYT) Form 4 transaction an open-market sale?
What does the F transaction code mean in the Veracyte (VCYT) Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.